Latest news with #Cigna
CBS News
13 hours ago
- Health
- CBS News
Allegheny Health Network and Cigna Healthcare announce 3-year contract agreement
On Friday, Allegheny Health Network and Cigna Healthcare announced a new, three-year contract agreement that will ensure those on Cigna insurance will continue to have access to AHN facilities. "This contract is fantastic news for the more than 20,000 Cigna members in this region who rely on AHN for their care," said AHN President Mark Sevco. "It ensures continued, in-network access to AHN's expert clinicians, and to the exceptional-quality, high-value care that their members and our patients expect and deserve." Beneficiaries will continue to have in-network access to AHN's clinical programs, 14 hospitals, and the doctors and specialists employed by AHN. Patients who have appointments in the next week will still be able to keep them, and the new contract goes through June 30, 2028. Those covered by Cigna insurance who may have questions about the new contract can call the Cigna customer service line at 1-800-997-1654.
Forbes
a day ago
- Business
- Forbes
Best Buy Appoints Neal Sample As New Technology Chief To Boost Digital Strategy
A Best Buy retail store Best Buy has named Neal Sample as its new chief digital and technology officer, bringing in a seasoned executive with a wide-ranging background to accelerate the company's digital transformation. He will start on July 14, 2025 Sample most recently served as executive vice president and CIO at Walgreens Boots Alliance, where he held the role for just under two years. That was proceeded by the CIO post at Northwestern Mutual and being promoted from CIO to COO of Express Scripts prior to its purchase by Cigna. He is also a past Group President of Enterprise Growth at American Express. Sample also has a PhD in Computer Science from Stanford University. Neal Sample He succeeds Brian Tilzer, who joined Best Buy in 2018 and carried the title of Chief Digital, Analytics, and Technology Officer of the company. He joined Best Buy after having been the Chief Digital Officer of CVS Health. In a note to employees, CEO Corie Barry praised Sample's breadth of experience across both traditional and tech-driven organizations. 'Neal has a unique background, having spent time in legacy businesses as well as in high-tech and digitally native companies,' Barry wrote, the latter referring to Sample's stints at the likes of eBay and Yahoo!. She also noted that his leadership approach is expected to help Best Buy move 'with greater speed, clarity and conviction.' 'I'm thrilled to join Best Buy at such a pivotal moment,' Sample underscored. 'It's a brand I've long admired with a strong foundation and a clear commitment to innovation. I'm excited to partner with the team to accelerate digital initiative and deliver increasing value to customers.' The leadership change comes as Best Buy works to sharpen its digital edge in an increasingly competitive consumer electronics landscape. Peter High is President of Metis Strategy, a business and IT advisory firm. He has written three bestselling books, including his latest Getting to Nimble. He also moderates the Technovation podcast series and speaks at conferences around the world. Follow him on Twitter @PeterAHigh.
Yahoo
a day ago
- Health
- Yahoo
Cigna Enables Coverage for RhinAer®
Policy Update Validates Clinical Value and Expands Patient Access to Innovative Chronic Rhinitis Treatment MOUNTAIN VIEW, Calif., June 27, 2025--(BUSINESS WIRE)--Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced that Cigna Healthcare will provide coverage for RhinAer® treatment of the posterior nasal nerve (CPT 31242), effective September 15, 2025. This change removes RhinAer from Cigna's list of procedures deemed experimental, investigational, and unproven, marking a significant step forward in expanding access to a best-in-class treatment option for patients suffering from the debilitating effects of chronic rhinitis. Starting September 15, over 15 million Cigna members and their healthcare providers will gain access to this clinically proven solution for patients with chronic rhinitis, a persistent inflammatory condition that significantly compromises quality-of-life. Cigna's policy update highlights the growing recognition of RhinAer's clinical efficacy and net health benefit as a non-invasive alternative to surgery or long-term, ineffective medication and clinic-based management. "Cigna's decision is a pivotal milestone in expanding physician and patient access to RhinAer — already used to treat more than 50,000 patients," said Matt Brokaw, CEO of Aerin Medical. "Alongside recent coverage expansion by Blue Cross of Idaho, this momentum underscores the compelling evidence for this procedure and its significant benefit for sufferers. We are grateful for our partnership with the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) and EVP/CEO Dr. Rahul K. Shah, MD, MBA, and for the significance of our combined voice in elevating awareness of this condition's burden." "Chronic rhinitis takes a substantial toll on patients and Cigna's decision is a welcome development that empowers physicians to offer critical solutions to appropriate patients," said Dr. Gavin Setzen, CEO & President of Albany ENT & Allergy Services, P.C., and Associate Clinical Professor of Otolaryngology-Head & Neck Surgery at Albany Medical Center, and past president of AAO-HNS. "With strong evidence from 20 peer-reviewed publications and multi-study evidence of three-year durability, we know that RhinAer works. I am pleased that Cigna's decision supports the adoption of a therapy that elevates the standard of care for patients." Information for Providers: The codes 31242 - Nasal/sinus endoscopy, surgical; with destruction by radiofrequency ablation, posterior nasal nerve and 31243 - Nasal/sinus endoscopy, surgical; with destruction by cryoablation, posterior nasal nerve have been removed from experimental / investigational status and will not require precertification. For more information about Cigna's updated medical policy for RhinAer (CPT 31242), visit: About RhinAer Using temperature-controlled, radiofrequency technology, RhinAer features a thin, wand-like stylus that is inserted via the nostril to deliver precise therapeutic benefits, while sparing surrounding tissues. RhinAer directly disrupts the posterior nasal nerve (PNN) that triggers excessive mucus production, treating an underlying cause of chronic rhinitis. RhinAer provides ENT physicians with a comprehensive solution for the treatment of chronic rhinitis, addressing sources of rhinorrhea and congestion. The procedure can be performed with a local anesthetic during an office visit, with no incisions, minimal to no downtime, and little discomfort. RhinAer initially received FDA 510(k) clearance in December 2019 and CE Mark in 2020. For more information, visit About Aerin Medical Aerin Medical is a privately held, venture-backed company, headquartered in Mountain View, California. Aerin's mission is to expand access to meaningful relief for millions of patients suffering from chronic ENT conditions. The company's products, VivAer® for nasal airway obstruction and RhinAer® for chronic rhinitis, leverage Aerin's proprietary temperature-controlled technology, which allows ENT physicians to reliably improve patients' symptoms with unique technologies that are appealing alternatives to invasive surgery. More than 150,000 patients have been treated with Aerin Medical products to date. For more information, please visit and follow Aerin Medical on Facebook, X, Instagram, LinkedIn and YouTube. View source version on Contacts Media Contact: Michael FanucchiAerin Medicalmfanucchi@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
a day ago
- Health
- Associated Press
Cigna Enables Coverage for RhinAer®
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Jun 27, 2025-- Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced that Cigna Healthcare will provide coverage for RhinAer ® treatment of the posterior nasal nerve (CPT 31242), effective September 15, 2025. This change removes RhinAer from Cigna's list of procedures deemed experimental, investigational, and unproven, marking a significant step forward in expanding access to a best-in-class treatment option for patients suffering from the debilitating effects of chronic rhinitis. Starting September 15, over 15 million Cigna members and their healthcare providers will gain access to this clinically proven solution for patients with chronic rhinitis, a persistent inflammatory condition that significantly compromises quality-of-life. Cigna's policy update highlights the growing recognition of RhinAer's clinical efficacy and net health benefit as a non-invasive alternative to surgery or long-term, ineffective medication and clinic-based management. 'Cigna's decision is a pivotal milestone in expanding physician and patient access to RhinAer — already used to treat more than 50,000 patients,' said Matt Brokaw, CEO of Aerin Medical. 'Alongside recent coverage expansion by Blue Cross of Idaho, this momentum underscores the compelling evidence for this procedure and its significant benefit for sufferers. We are grateful for our partnership with the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) and EVP/CEO Dr. Rahul K. Shah, MD, MBA, and for the significance of our combined voice in elevating awareness of this condition's burden.' 'Chronic rhinitis takes a substantial toll on patients and Cigna's decision is a welcome development that empowers physicians to offer critical solutions to appropriate patients,' said Dr. Gavin Setzen, CEO & President of Albany ENT & Allergy Services, P.C., and Associate Clinical Professor of Otolaryngology-Head & Neck Surgery at Albany Medical Center, and past president of AAO-HNS. 'With strong evidence from 20 peer-reviewed publications and multi-study evidence of three-year durability, we know that RhinAer works. I am pleased that Cigna's decision supports the adoption of a therapy that elevates the standard of care for patients.' Information for Providers: The codes 31242 - Nasal/sinus endoscopy, surgical; with destruction by radiofrequency ablation, posterior nasal nerve and 31243 - Nasal/sinus endoscopy, surgical; with destruction by cryoablation, posterior nasal nerve have been removed from experimental / investigational status and will not require precertification. For more information about Cigna's updated medical policy for RhinAer (CPT 31242), visit: About RhinAer Using temperature-controlled, radiofrequency technology, RhinAer features a thin, wand-like stylus that is inserted via the nostril to deliver precise therapeutic benefits, while sparing surrounding tissues. RhinAer directly disrupts the posterior nasal nerve (PNN) that triggers excessive mucus production, treating an underlying cause of chronic rhinitis. RhinAer provides ENT physicians with a comprehensive solution for the treatment of chronic rhinitis, addressing sources of rhinorrhea and congestion. The procedure can be performed with a local anesthetic during an office visit, with no incisions, minimal to no downtime, and little discomfort. RhinAer initially received FDA 510(k) clearance in December 2019 and CE Mark in 2020. For more information, visit About Aerin Medical Aerin Medical is a privately held, venture-backed company, headquartered in Mountain View, California. Aerin's mission is to expand access to meaningful relief for millions of patients suffering from chronic ENT conditions. The company's products, VivAer ® for nasal airway obstruction and RhinAer ® for chronic rhinitis, leverage Aerin's proprietary temperature-controlled technology, which allows ENT physicians to reliably improve patients' symptoms with unique technologies that are appealing alternatives to invasive surgery. More than 150,000 patients have been treated with Aerin Medical products to date. For more information, please visit and follow Aerin Medical on Facebook, X, Instagram, LinkedIn and YouTube. View source version on CONTACT: Media Contact: Michael Fanucchi Aerin Medical [email protected] KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: PROFESSIONAL SERVICES HEALTH INSURANCE OTHER HEALTH HEALTH INSURANCE GENERAL HEALTH PHARMACEUTICAL SOURCE: Aerin Medical Inc. Copyright Business Wire 2025. PUB: 06/27/2025 11:00 AM/DISC: 06/27/2025 11:01 AM
Business Wire
a day ago
- Health
- Business Wire
Cigna Enables Coverage for RhinAer ®
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced that Cigna Healthcare will provide coverage for RhinAer ® treatment of the posterior nasal nerve (CPT 31242), effective September 15, 2025. This change removes RhinAer from Cigna's list of procedures deemed experimental, investigational, and unproven, marking a significant step forward in expanding access to a best-in-class treatment option for patients suffering from the debilitating effects of chronic rhinitis. Starting September 15, over 15 million Cigna members and their healthcare providers will gain access to this clinically proven solution for patients with chronic rhinitis, a persistent inflammatory condition that significantly compromises quality-of-life. Cigna's policy update highlights the growing recognition of RhinAer's clinical efficacy and net health benefit as a non-invasive alternative to surgery or long-term, ineffective medication and clinic-based management. 'Cigna's decision is a pivotal milestone in expanding physician and patient access to RhinAer — already used to treat more than 50,000 patients,' said Matt Brokaw, CEO of Aerin Medical. 'Alongside recent coverage expansion by Blue Cross of Idaho, this momentum underscores the compelling evidence for this procedure and its significant benefit for sufferers. We are grateful for our partnership with the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) and EVP/CEO Dr. Rahul K. Shah, MD, MBA, and for the significance of our combined voice in elevating awareness of this condition's burden.' 'Chronic rhinitis takes a substantial toll on patients and Cigna's decision is a welcome development that empowers physicians to offer critical solutions to appropriate patients,' said Dr. Gavin Setzen, CEO & President of Albany ENT & Allergy Services, P.C., and Associate Clinical Professor of Otolaryngology-Head & Neck Surgery at Albany Medical Center, and past president of AAO-HNS. 'With strong evidence from 20 peer-reviewed publications and multi-study evidence of three-year durability, we know that RhinAer works. I am pleased that Cigna's decision supports the adoption of a therapy that elevates the standard of care for patients.' Information for Providers: The codes 31242 - Nasal/sinus endoscopy, surgical; with destruction by radiofrequency ablation, posterior nasal nerve and 31243 - Nasal/sinus endoscopy, surgical; with destruction by cryoablation, posterior nasal nerve have been removed from experimental / investigational status and will not require precertification. For more information about Cigna's updated medical policy for RhinAer (CPT 31242), visit: About RhinAer Using temperature-controlled, radiofrequency technology, RhinAer features a thin, wand-like stylus that is inserted via the nostril to deliver precise therapeutic benefits, while sparing surrounding tissues. RhinAer directly disrupts the posterior nasal nerve (PNN) that triggers excessive mucus production, treating an underlying cause of chronic rhinitis. RhinAer provides ENT physicians with a comprehensive solution for the treatment of chronic rhinitis, addressing sources of rhinorrhea and congestion. The procedure can be performed with a local anesthetic during an office visit, with no incisions, minimal to no downtime, and little discomfort. RhinAer initially received FDA 510(k) clearance in December 2019 and CE Mark in 2020. For more information, visit About Aerin Medical Aerin Medical is a privately held, venture-backed company, headquartered in Mountain View, California. Aerin's mission is to expand access to meaningful relief for millions of patients suffering from chronic ENT conditions. The company's products, VivAer ® for nasal airway obstruction and RhinAer ® for chronic rhinitis, leverage Aerin's proprietary temperature-controlled technology, which allows ENT physicians to reliably improve patients' symptoms with unique technologies that are appealing alternatives to invasive surgery. More than 150,000 patients have been treated with Aerin Medical products to date. For more information, please visit and follow Aerin Medical on Facebook, X, Instagram, LinkedIn and YouTube.
